Prelude Therapeutics Inc

Prelude Therapeutics Incorporated is a precision oncology company focused on developing new cancer medicines for patients with limited treatment options. The company, founded in 2016, uses its expertise in cancer biology, medicinal chemistry, and clinical development to identify biological targets and create new chemical entities (NCEs) for clinical trials. Prelude has received multiple investigational new drug application (IND) clearances from the U.S. Food and Drug Administration (FDA) and has advanced several programs into clinical trials. Prelude's pipeline includes diverse programs such as kinases, targeted protein degraders, and precision antibody drug conjugates. The company is also collaborating with AbCellera Biologics, Inc. on an early-stage discovery program involving potent degraders as payloads for novel antibodies targeting tumor-specific antigens. Additionally, Prelude has other proprietary programs in various stages of preclinical development. The company aims to address diseases with high unmet medical needs by developing highly potent and specific agents against clinically validated targets, utilizing advances in new therapeutic modalities like targeted protein degradation.